Jan 2 (Reuters) – India has approved the COVID-19 vaccine developed by AstraZeneca and Oxford University, paving the way for the world’s second most populous country to join the list of nations launching immunisation campaigns. The following gives the state of play of the main vaccine candidates that are being rolled out, are pending approval or are in late stage testing. COMPANY STAGE OF DEVELOPMENT EXPECTED DOSES Pfizer Inc and U.S., Britain, Canada, EU, (Nine countries for over 600 mln BioNTech SE Switzerland, Bahrain, Qatar, doses) Mexico, Saudi Arabia, Singapore and Chile have approved or U.S. – 200 mln + option for 400 authorized emergency use of the mln more shot. Roll-out underway in Britain, U.S., EU, Mexico and UK – 40 mln; Expects to have 10 Singapore. Pfizer and Brazil mln doses by end of 2020 regulator are in talks to speed up emergency approval. EU – 300 mln; 12.5 mln by end of 2020 Canada – Minimum of 20 mln doses (500,000 in Jan) Japan – 120 mln Colombia – 1.7 mln in Feb South Korea – 20 mln Iraq – 1.5 mln Chile – 10 mln Malaysia – 12.8 mln Moderna Inc Distribution begins in Canada and U.S. – 200 mln (20 mln by Dec, 80 the United States. mln in Q1 and 100 mln in Q2) EU – 160 mln UK – 7 mln Japan – 50 mln or more, to be distributed by Takeda Switzerland – 7.5 mln Canada- 40 mln Israel – 6 mln, expects to begin receiving the vaccines by March “at the latest” Singapore – Not specified Qatar- Not specified South Korea – 20 mln Johnson & Johnson Completes enrollment in first U.S. – 100 mln + 200 mln more late-stage trial of its COVID-19 under subsequent agreement single-dose vaccine candidate; plans to submit emergency use UK – 30 mln + option for up to 22 application to FDA in Feb. mln more EU – 200 mln + 200 mln additional Canada – Up to 38 mln Japan – Not Applicable South Korea – 4 mln AstraZeneca & Oxford UK health regulators approved (More than 15 countries and University emergency use of vaccine first, groups for over 3 bln doses) with vaccinations expected to begin early in the new year. U.S. – 300 mln Argentina, El Salvador and India have also approved the shot. UK – 4 mln doses this year (delivery schedule pushed back after trial results; Earlier 30 mln doses were expected with initial deliveries by Sept/Oct Mexico and Brazil are eyeing 2020) speedy approvals as well, while Europe said it would need more EU – At least 300 mln + 100 mln data and time to make a decision. additional Italy, Germany, the Netherlands and France – 300 mln + 100 mln additional Canada – Up to 20 mln Japan – 120 mln Bangladesh – 30 mln (through India’s Serum Institute) Colombia – 10 mln South Korea – 20 mln The Philippines – 2.6 mln Malaysia – 6.4 mln Sinovac Biotech Ltd Vaccine approved for emergency Indonesia – 125 mln with 1.2 mln use in China in July. Turkish doses already secured researchers said the shot was 91.25% effective based on an Brazil – 46 mln doses (10.8 mln interim analysis. by Dec. 31) Turkey – 50 mln doses The Philippines to finalise negotiations for 25 mln doses Gamaleya Research Institute Russia stops new volunteer Supply deals with over 10 enrollment in late stage trial of countries including India, its COVID-19 vaccine, Sputnik V. Brazil, Algeria, Bolivia and Mass inoculation underway in Argentina for at least 280 mln Russia since Dec. Belarus begins doses. Russia to distribute over administering Sputnik V. one million shots at home by year-end. CanSino Biologics Inc Approved for use in Chinese Mexico – 10 mln-35 mln doses military. Late-stage trial underway in Pakistan and Mexico. Under regulatory review in Mexico. Sinopharm Group Co Ltd China approved the shot developed Expects to produce more than 1 by an affiliate of Sinopharm, bln doses in 2021 whose efficacy was pegged at 79.34% by the company. Pakistan to purchase 1.2 million doses UAE, however, had said Sinopharm vaccine has 86% efficacy against COVID-19; The vaccine has already been used on about 1 mln people in China in an emergency program. Bharat Biotech Has sought emergency-use In talks with at least 10 authorization from the Indian countries in South America, Asia drug regulator for its and Eastern Europe vaccine. Novavax Inc Late-stage 30,000-participant U.S. – 100 mln study begins in U.S. . Interim data from UK – 60 mln ongoing late-stage study in UK is expected in first quarter of Canada – Up to 76 mln 2021. Japan – 250 mln Australia – 40 mln The Philippines – 30 mln by July 2021 Indonesia – 30 mln New Zealand – 10.7 mln Medicago Begins mid-to-late stage studies No supply deals yet of its experimental vaccine and a booster from GlaxoSmithKline . Anhui Zhifei Longcom Begins Phase 3 trials, planning No supply deals yet Biopharmaceutical to recruit 29,000 volunteers across the world (https://bit.ly/3mc5WUI) (Reporting by Amruta Khandekar, Dania Nadeem, Mrinalika Roy, Vishwadha Chander, Manas Mishra, Muvija M and Pushkala Aripaka in Bengaluru; Editing by Sriraj Kalluvila, Anil D’Silva and Mark Potter)
Our Standards: The Thomson Reuters Trust Principles.